ZOLL Never Enters Patients in Fading SSCORE Registry Study at Minneapolis Heart Institute of the Abbott Northwestern Hospital in the US

CHELMSFORD, Massachusetts, USA –

ZOL^®an employee of Asahi Kasei, the medical device and associated software solutions, who enrolled the first patients in the SSCORE registry study (Sabove Ssaturated oxygen Cextended Oobserving REGARDINGessence) taken. The prospective study could be conducted, another study on the effect of SuperSaturated Oxygen Therapy (SSO)₂) to reduce heart failure and mortality in heart failure patients with a STD-myocardial infarction of the left anterior wall artery (LAD STEMI). LAD STEMI heart failure is the most severe form of heart failure and has been upgraded to a higher level as the “Witwenmacher” occupation. There is an SSCORE date that can provide major cost savings to the health care system during the prevention of heart failure that offers palliative palliative treatment strategies after lung treatment.

The Minneapolis Heart Institute at Abbott Northwestern Hospital, a multi-site partner hospital of Allina Health in Minneapolis, Minnesota, will submit the Frühzeitigen application for the short SSO₂-Therapy and what follows from the first study material.

“These patients with LAD closure are one of the risks that are taken. The artery of the artery is the first step, separated is the Anwendung of SSO₂ for further reduction of the infarction. If most patients have a proximal LAD version, and I want to have the best chance of re-functioning the disease, so Dr. M. Nicolas Burke, Leader of the Cardiovascular Note of Abbott Northwestern, of the federal government that treats patients, was included in the SSCORE Program.

“The first patient enrollment in the SSCORE trial is an investigation into the further development of supersaturated oxygen therapy for the treatment of stroke,” said Matt Rochner, CEO of ZOLL TherOx. “The SSO₂-Therapy does not only have the potential, the treatment for the patients who are improved, can bear some of the long-term treatment costs for heart-sufficient care, which is a major improvement for overall health. A partner of the Minneapolis Heart Institute and Allina Health offers one of the best services, one of these top technology advances, with more evidence for clinical and economic data, together and the SSO₂-Therapie zum neuen Treatmentstandard for the care of LAD-STEMI-Patients.”

Patients with LAD-STEMI heart attack have a higher mortality rate than patients with other heart attack types. Death SSO₂-Therapy is the first and only FDA approved treatment that significantly reduces herniated disc disease following coronary angioplasty with stenting.¹ The use of the heart muscles is one of the most important recommendations for the further course of treatment or the treatment of a heart failure.²

The SSO₂-Therapy is a very caring treatment for individualized patients, who leads a LAD STEMI and is treated internally by such hours after treatment of the chest with a conventional stent. The therapy is carried out by the recovery of the recovery after the treatment of the heart operation during angioplasty and stent placement of high quality and acid acid (7- to 10-fold higher than normal in the blood circulation vorhand). More clinical studies are focused on the safety and work of SSO₂-Therapie in Bezug auf de Verringerung der Infarktgröße invests, which darstellt a heavier prädiktor for spätere Behandlungsergebnisse.^1,3–6

“The focus on minimal infarct size and improvement of microvascular function with SSO₂ In the Catheter Laboratory in the research on the deterioration of the Erkrankung there is a single-handed approach, on which the man in this area has long been tangled,” reports Dr. Jay Traverse, director of the Prüfarzt and Researcher of Allina’s Minneapolis Heart Institute Foundation and interventional cardiologist at Allina’s Minneapolis Heart Institute. “The end of treatment of these patients, who have a standard treatment with a stenting of the LAD, represents a renewed treatment, represents more like two years one of the few re-examinations. The supersaturated oxygen therapy has a potential effect, whereby this problem is reduced, the quality of the patient is improved and the last round of funding is carried out by the health care system. We congratulate ourselves on the participation of this study and see its results with pure vision in total.”

About ZOL

ZOLL, a company of Asahi Kasei, has developed a medical device and software solution that can improve patient outcomes, life, and clinical and clinical efficiency on the scaffolding. With products for defibrillation and heart rate monitoring, heart rate improvement and HLW feedback, saturation therapy, data management, beat management, temperature management therapies for sleep apnea diagnosis and treatment, a number of umfassende spectrum and technology, the clinics, rescue and fire protection as well as leg aids help to improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group has the world of life and people’s lives. Since the beginning of the year 1922 as the lover of ammonia and zellulose phases, this is the result of the proactive Transformation of the Geschäftsportfolios, which the group is constantly aware of. With more than 49,000 dollars, part of the company is offered a nachhaltige gesellschaft, but it compensates with its three major debt burdens for the great recovery of human rights. This Geschäftsfelder is: Materials, Heimbedarf and Gesundheit. Zum Bereich Gesundheit gehören Geräte und Systeme für Akutmedizin, Dialysis, therapeutic Apheresis as well as Herstellung von Biotherapeutika, Medicamenten und diagnostic Reagenzien. More information can be found at: www.asahi-kasei.com.

Asahi Kasei embarked on a national initiative and began working toward becoming a carbon-neutral enterprise by 2050. More information can be found at https://www.asahi-kasei.com/sustainability/.

¹ Steen GW, et al. Circ Cardiovasc Intervent 2009; 2: 366-75.

² Stone GW et al. J Am Coll Cardiol. 2016;67(14):1674–83.

³ O’Neill WW, et al. Jour of Am Coll Cardiol. 2007;50:5:397-405.

⁴ David SW, et al. Catheter Cardiovasc Interv. 2018;1–9.

⁵https://www.cms.gov/Medicare/Coding/ICD10/Downloads/2020-ICD-10-PCS-Guidelines.pdf

⁶ Chen S, et al. Catheter Cardiovasc Interv. 2020; 1–7.

Copyright ©2024 ZOLL Medical Corporation. All rights reserved. ZOLL and TherOx are a subsidiary of ZOLL Medical Corporation and/or other jointly owned companies in the U.S. and/or other states. Asahi Kasei is one of the subsidiaries of Asahi Kasei Corporation. All other subsidiaries are owned by the jewelry.

The general text, in the original text that is light, is the official and authorized version. The settings must be adjusted. Only the Sprachversion, the original veröffentlichte wurde, is legally valid. Use the original version of the display ab.